Summary Macrophage inflammatory protein la (MIP-1a) inhibits haemopoietic stem cell proliferation. This property has been exploited in a murine chemotherapy model and has been shown to ameliorate cytotoxic-induced myelosuppression after S-phase-specific cytotoxic therapy. We have now shown that BB-10010, a stable mutant of MIP-la, (a) is more effective when administered as a continuous infusion than when bolus injected and (b), when administered via a 7-day infusion during and after cyclophosphamide treatment, results in an earlier recovery of leucocyte numbers. This effect was accompanied by progenitor cell mobilization into the peripheral blood and included primitive cells with marrow-repopulating ability (MRA). Maximal mobilization and recovery of leucocytes occurred when MIP-1a was combined with granulocyte colony-stimulating factor (G-CSF) therapy. The findings suggest that MIP1-a used alone or in combination with G-CSF may allow delivery of a greater chemotherapy dose intensity as a consequence of both accelerated leucocyte recovery and maintenance of high-quality mobilized progenitor cells for harvesting and peripheral blood stem cell transplantation.
improvement in the kinetics of neutrophil recovery (Dunlop et al, 1992) . It now appears that MIP-ax possesses additional properties to that of simple cell cycle inhibition. Analysis of stem cell (CFU-S) recovery following HU and MIP-l a suggests that MIP-I a may also modulate the self-renewal and differentiation capacity of the stem cell population (Lord, 1995) . Self-renewal of CFU-S during the recovery period was 50% higher than during untreated recovery. The resultant increase in the stem cell pool was then more than sufficient to offset the complementary reduction in differentiation rate and thus allowed the more rapid neutrophil recovery. This, together with the recent report that MIP-la mobilizes haemopoietic progenitor cells , suggests that MIP-la may offer further therapeutic benefit when used in conjunction with the more clinically relevant, non-S-phasespecific cytotoxic agents.
Evaluation of MIP-la has been hindered by a tendency of the native protein to undergo aggregation and form high molecular weight polymers. BB-10010 represents a stable mutant carrying a single amino acid substitution of Asp26 => Ala with a reduced tendency to form polymers at physiological pH and ionic strength (Hunter et al, 1996) . The potency of BB-10010 appears to be similar to native MIP-1 a, as judged by receptor binding, calcium mobilization, thymidine suicide and murine myeloprotective experiments (Hunter et al, 1996) .
Here, we investigate the efficacy of continuous infusion of MIPla (as represented by BB-10010) compared with repeated bolus injection and demonstrate the beneficial effects of MIP-la on the recovery kinetics of bone marrow in a murine model of cyclophosphamide-induced bone marrow damage. 
Preparation of cell suspensions
Blood was collected by terminal cardiac puncture under light anaesthesia (ethrane) and pooled from the various groups of donor mice. Heparin (25 ,u ml-') was used as an anticoagulant. Leucocyte counts were performed on an automated counter (Sysmex). Bone marrow cells were harvested by flushing the femur with Fischer's medium using a 21G needle as previously described (Lord, 1993) .
Colony assays Eight-and 12-day CFU-S (CFU-S8, CFU-S,2) and cells with marrow-repopulating ability (MRA) were assayed as described in detail previously (Lord, 1993) . Briefly, mice (groups of 20) were 
Experimental protocols
Two separate experimental protocols were designed to determine (a) the optimal schedule of MIP-la delivery using a previously described model of repeated sublethal irradiation (Lord, 1996) and (b) to investigate the myeloprotective and mobilization properties of MIP-ax against cyclophosphamide.
MIP-1la scheduling
Groups of three mice were irradiated with 4.5-Gy whole-body yrays. They were administered MIP-la or placebo (phosphatebuffered saline) either by subcutaneous injection for 7 days or subcutaneous infusion using an inplanted 7-day mini-osmotic pump (Alzet 2001). Pumps were inserted under short-acting anaesthetic (ethrane) at variable time points (3-4 h before or 24 h or 7 days after irradiation) and removed 3 or 7 days later. After 14 days, this cycle of radiation and treatment was repeated. In all experiments, groups of three mice were killed at day 14 of treatment cycle 2 and their femoral marrow assayed, in this experiment, for CFU-SIO.
Myeloprotection against cyclophosphamide and mobilization of progenitor cells
Groups of three mice received a single i.p. injection of cyclophosphamide and the appropriate treatment with MIP-la, G-CSF or both. MIP-lix was administered for 7 days using a mini-pump inserted under short-acting anaesthetic, approximately 3 h before cytotoxic treatment. G-CSF (100 gg kg-') was injected subcutaneously twice daily from day 3 to day 7. Control mice received cyclophosphamide only. Femoral bone marrow cellularity and CFU-S were assayed at time points between days 1 and 14. Peripheral white blood cell (WBC) counts were made daily from day 1 to day 10, and the mobilized progenitor cells were assayed daily from day 4 to day 7 after cyclophosphamide treatment.
Statistical analysis
For each experiment, the means of the respective haematological parameters were calculated and expressed as means ± standard error plotted against time. When appropriate, results were analysed using a two-sided Student's t-test. RESULTS MIP-la scheduling and irradiation Effect of continuous infusion of MIP-la on CFU-S recovery following irradiation Table 1 shows the results of three separate studies comparing the effects of timing and bolus vs continuous administration of MIPla. Two cycles of 4.5-Gy y-ray irradiation reduced the femoral CFU-S1o to approximately 10% of normal (458 ± 51) at day 14.
The continuous administration of MIP-la increased the CFU-S recovery to 1250 (P < 0.001) and 800 CFU-S per femur (P < 0.05) after 7-day and 3-day infusions respectively (study I, Table 1 ). This effect of MIP-la was lost when the same total dose was administered as a daily (711 CFU-S per femur, P > 0.1) or twice daily (550 CFU-S per femur, P > 0.1) bolus injection (study II, Table 1 ). Finally, the response to MIP-la was dependent on the timing of administration relative to the myelosuppressive insult (study III, Table 1 ). Commencement of 7-day continuous MIP-laX treatment immediately preceding irradiation conferred maximal advantage. An attenuated effect (960 ± 69) was evident when the MIP-la infusion was commenced 24 h after irradiation and was totally abrogated when administered during the second half of each cycle (690 ± 64).
Myeloprotection against cyclophosphamide and mobilization of progenitor cells Bone marrow recovery Bone marrow cellularity (Figure 1) showed a similar degree of suppression at day 1, following cyclophosphamide, irrespective of additional MIP-la treatment. MIP-Iat did however generate an Results show the mean ± s.e. of three experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
British Journal of Cancer (1997) 75 (12), 1715-1720 nadir leucocyte count of 1.6 ± 0.1 x 109 1-'. Mice receiving concurrent MIP-la developed a similar nadir (2.0 ± 0.5 x 109 1') but recovered to control leucocyte numbers 1 day earlier (day 6) (P < 0.01) and overshot twofold by day 7. Leucocyte recovery was enhanced by the addition of either MIP-la or G-CSF treatment (Table 2) . On its own, MIP-la resulted in only a modest twofold improvement in the rate of leucocyte recovery compared with control -normal levels were reached by day 6 compared with day . genitor cells into the peripheral blood. The enhanced mobilization seen with MIP-1 a was reflected by a more rapid reduction in day 8 CFU-S between day 4 and day 6. At day 7, femoral CFU-S iof recovery at day 4 (12.7 ± 2.9 x 106 per femur vs numbers were similar in both groups (cyclophosphamide 630 ± 40 106 per femur, P = 0.05). Recovery to control numbers vs MIP-la 450 ± 50, P > 0.05) despite a 2.4-fold increase in te in both groups by day 8.
mobilized CFU-S in the MIP-la-treated cohort.
The recovery patterns of the day 8 CFU-S and day 12 CFU-S populations are shown in Figure 2 . Cyclophosphamide induced a rapid fall in both CFU-S populations with a nadir occurring at day 1. By 14 days, both CFU-S8 and CFU-S12 were approaching their normal numbers (approximately 3500 per femur) having demonstrated an abortive recovery phase by around day 4. The 8-day CFU-S were more sensitive to the cytotoxic effects of cyclophosphamide when comparing day 1 survivals in both populations (CFU-S8 217 ± 37 per femur vs CFU-S12 930 + 70 per femur, P < 0.001). Co-administration of MIP-la neither provided any measurable protection to the cells from their initial depletion nor enhanced their recovery in the first 8 days. Although the MIP-la-treated groups had consistently higher day 8 and day 12 CFU-S numbers during the later regeneration period, the difference was small and fell within one standard error of the means by day 14.
Leucocyte recovery
The total leucocyte counts over 10 days after cyclophosphamide treatment are shown in Figure 3 . For the first 3 days, the WBC remained in the normal range after which cyclophosphamide treatment produced a short-lasting leucopenia (days 4-6) with a mean DISCUSSION MIP-lIx has been shown to protect multipotential haemopoietic progenitor cells against repeated treatments with S-phase chemotherapeutic drugs (Dunlop et al, 1992; Lord et al, 1992) , however it remains to be seen whether a similar stratagem will alleviate the myelosuppressive effects of the more clinically relevant, non-S-phase-specific anti-cancer agents.
We have devised a 7-day schedule of continuous MIP-a (40 jg per mouse day-') administered via an implanted subcutaneous pump and inserted before chemotherapy. This dosing schedule was based on extensive preclinical studies with MIP-la, including a murine model of MIP-la-induced radioprotection (Lord et al, 1996) . In this model, MIP-la attenuated the incremental bone marrow damage associated with repeated treatments with sublethal irradiation (450 rads y-rays every 14 days for four cycles ; Lord et al, 1996) . No direct myeloprotection was observed but the cumulative effects of the enhanced recovery of CFU-Ss became most notable during the later cycles of treatment. Mechanistically, the observed response to MIP-la was felt to be most consistent with an improved self-renewal capability of the surviving CFU-Ss, Results show the means ± s.e. of three experiments. 1 p < 0.05, 2p < 0.01, 3P < 0.02, 4 < 0.001. and it therefore suggests a possible role in bone marrow protection against a wide range of cytotoxic chemotherapy irrespective of S-phase specificity. The results reported here confirmed our earlier findings (Lord et al., 1996) , with enhanced CFU-S numbers in the MIP-la-treated mice after two cycles despite a lack of direct radioprotection (-1200 CFU-S per femur, Table 1 ). Recovery enhancement was most evident after the use of a protracted 7-day infusion and, furthermore, the response was dependent on the timing of administration, with maximal effects apparent when MIP-la was commenced before the irradiation treatment. Delaying treatment for 24 h resulted in an attenuated response, while delaying treatment until the second week of recovery had no effect on CFU-S regeneration. Bolus injection of MIP-la as a once-or twice-daily dose also failed to reproduce the advantage conferred by infused MIP-la, despite the administration of an identical total dose (40 ,ug per mouse per day).
The results from the cyclophosphamide studies, using an optimal MIP-la schedule, showed that, as with radiation, a 7-day infusion of MIP-1 a conferred little or no measurable direct protection on CFU-S against either the initial degree of damage incurred or against recovery in the first cycle of treatment. In addition, MIP-1 a failed to attenuate the abortive recovery which characterizes CFU-S kinetics after treatment with cyclophosphamide (Molineux et al, 1986) . A consistent feature of the cyclophosphamide model was a modest improvement in CFU-S recovery in the MIP-la-treated mice (Figure 2 ). This small recovery advantage, while not statistically significant, is consistent with the observations during the radiation model (Lord et al, 1996) in which MIP-la produced only a small benefit after one cycle. The therapeutic benefit of MIP1-a may be more evident when assessed over multiple cycles of chemotherapy, as shown in the radiation model (Lord et al, 1996) . However, our own observations and those of others (Molineux et al, 1986) suggest that repeated cycles of cyclophosphamide do not result in a useful model of cumulative bone marrow damage. As a consequence, we are now investigating the use of more 'stem cell-specific' agents (BCNU and busulphan) as more representative models of bone marrow damage that can usefully be protected by MIP-la.
Bone marrow regeneration after cyclophosphamide was associated with peripheral blood stem cell mobilization, an effect that was greatly enhanced by concurrent growth factor administration. This property has been well described and has been exploited clinically for transplantation purposes (Passos-Coelho et al, 1995) . Lord et al (1995) have recently shown that MIP-la also increases blood leucocyte numbers and progenitor cell release in mice. MIP-la preferentially mobilized the more primitive progenitor cells with marrow-repopulating ability (MRA) and significantly enhanced the mobilization induced by G-CSF. We now find that MIP-1 a enhances leucocyte recovery following cyclophosphamide and that this is mirrored by a significant increase in circulating CFU-S and MRA numbers (Tables 2 and 3 ). It is noticable that, with MIP-la, movement from the marrow is more rapid in the earlier stages and that CFU-S in the circulation are always higher than in the control group. During the earlier recovery phase, mobilization with MIP-I a exceeded that seen with G-CSF therapy. Combined treatment with MIP-la and G-CSF resulted in the most rapid leucocyte recovery and maximal progenitor cell mobilization, including cells with MRA.
The accelerated leucocyte recovery associated with MIP-la was similar to that observed in an earlier model using cytosine arabinoside (Dunlop et al, 1992) . In this instance, however, the recovery advantage occurred despite similar numbers of precursor cells in the bone marrow. This may represent an earlier release of bone marrow leucocyte stores, a property that may be common to all chemotactic factors (Jagel et al, 1992; Laterveer et al, 1995) . Alternatively, it may be the consequence of enhanced differentiation of committed progenitor cells by MIP-la, as has been suggested by a previous report (Keller et al, 1994) . It remains possible, however, that recovery enhancement is a consequence of an expanded CFU-S pool, itself the result of a subtle increase in stem cell self-renewal that is hidden by the simultaneous mobilization. Irrespective of the explanation, simultaneous observation of bone marrow and circulating stem cells shows that bone marrow parameters when viewed in isolation are not sufficient to allow full evaluation of MIP-la's cytoprotective properties.
In conclusion, MIP-1 a is a novel factor that has myeloprotective properties when used in conjunction with S-phase-specific cytotoxic chemotherapy. We now show that MIP-1 a, represented here as BB-10010, enhances leucocyte recovery and progenitor cell release after cyclophosphamide treatment. These effects complement G-CSF and suggest an adjunctive role with all classes of myelosuppressive chemotherapy, irrespective of their mode of cytotoxicity. Phase I and phase II clinical studies are now in progress to evaluate this hypothesis.
